Healthcare News

Birmingham, Alabama, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lyric Health, the award-winning telehealth service provider ranked #1 in the U.S. among all virtual care providers, has announced a strategic...

TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- As Ontario’s healthcare system faces unprecedented strain, Humber River Health is taking decisive action to help build a stronger, future-ready workforce...

Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior

BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today...

CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models,...

- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC...

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with...

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced...